Brief: Fusen Pharmaceutical Co Sees FY2022 Loss Attributable Between RMB30 Mln To RMB40 Mln
13/03/2023 14:37
March 13 (Reuters) - Fusen Pharmaceutical Co Ltd
1652.HK :
* SEES LOSS ATTRIBUTABLE TO RANGE BETWEEN RMB30 MILLION TO
RMB40
MILLION FOR FY2022
* EXPECTED RESULT DUE TO IMPAIRMENT LOSS ON GROUP'S AMOUNTS
DUE
FROM JIANGXI YONGFENG KANGDE FOR FY2022, AMONG OTHERS
Source text for Eikon: ID:
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA